Welcome to our dedicated page for Kodiak Sciences news (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences stock.
Kodiak Sciences Inc. (Nasdaq: KOD) is a precommercial, retina-focused biotechnology company whose news flow centers on clinical trial progress, scientific data presentations and capital markets activity. The company is developing biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), built on its proprietary ABC Platform and late-stage programs tarcocimab, KSI-501 and KSI-101.
On this page, readers can follow news about Kodiak’s Phase 3 studies, including GLOW2 in diabetic retinopathy, DAYBREAK in wet age-related macular degeneration, and the PEAK and PINNACLE studies in MESI. Company press releases describe milestones such as completion of enrollment in pivotal trials, new data from the Phase 1b APEX study of KSI-101, and updates on the performance of tarcocimab and KSI-501 in retinal vascular indications.
Kodiak Sciences also issues news about participation in major scientific and investor conferences, where its management and clinical collaborators present data on retinal programs and discuss the potential of IL-6 and VEGF targeting in eye disease. In addition, investors will find announcements related to public offerings of common stock and other financing activities, which the company uses to support its late-stage development and manufacturing efforts.
For anyone tracking KOD stock or developments in retinal biotechnology, this news feed offers a centralized view of Kodiak Sciences’ clinical, scientific and corporate updates as it advances its portfolio of investigational retinal medicines.
Kodiak Sciences (Nasdaq: KOD) announced its participation at the Glaucoma 360 New Horizons Forum 2025 on February 7, 2025, in San Francisco, where they will present their pipeline program for glaucoma treatment. The company is developing a groundbreaking dual-acting therapy using their Antibody Biopolymer Conjugate Drug (ABCD) platform.
The innovative 'duet' therapy targets both neuroinflammation and elevated intraocular pressure in glaucoma treatment. It specifically targets the NLRP3 inflammasome while incorporating an IOP-lowering molecule, designed for quarterly dosing. This approach aims to address the underlying mechanism of optic nerve damage in glaucoma, which affects approximately 76 million people worldwide.
Dr. Dolly Chang, Chief Scientific Officer, will present 'Addressing Optic Neuropathy Through Neuroinflammation Modulation and IOP Lowering with the ABCD Platform: A Polymedicine Approach to Glaucoma' as part of the session 'Beyond IOP: Targeting Neuroprotection and Vision Restoration.'
Kodiak Sciences (Nasdaq: KOD) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's CEO, Victor Perlroth, M.D., is scheduled to present on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time.
The presentation will be accessible through a live webcast on the 'Events and Presentations' section of Kodiak's investor relations website. The webcast recording will remain available for replay for a time after the event. Kodiak Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for various retinal diseases.
Nona Biosciences and Kodiak Sciences (Nasdaq: KOD) have announced a collaboration to develop novel multi-target antibodies for ophthalmic diseases. The partnership will utilize Nona's proprietary Harbour Mice® platform, which generates fully human monoclonal antibodies in both H2L2 and heavy chain-only (HCAb) formats.
The HCAb platform produces antibodies approximately half the size of conventional IgGs, offering significant advantages for next-generation therapies. Under the agreement, Kodiak Sciences gains rights to use both H2L2 and HCAb Harbour Mice® platforms for therapeutic antibody discovery and development across multiple programs.
Kodiak Sciences reported Q3 2024 financial results and business updates. The company hosted an Investor R&D Day, presenting new clinical data showing tarcocimab's ocular half-life of 20 days, 3 times longer than competitors. They continued enrollment in three clinical programs: Phase 3 GLOW2 study in diabetic retinopathy, DAYBREAK study in wet AMD, and APEX study for KSI-101. Financial results showed a net loss of $43.9 million ($0.84 per share), with cash position of $197.9 million expected to support operations into 2026. R&D expenses were $31.9 million, down from $36.2 million in Q3 2023.
Kodiak Sciences (Nasdaq: KOD), a biopharmaceutical company focused on retinal disease therapeutics, announced its participation in upcoming investor conferences.
Management will present at the Jefferies London Healthcare Conference on November 21, 2024, at 9:00 AM GMT in London, UK, and at the 7th Annual Evercore ISI HealthCONx Conference on December 3, 2024, at 2:35 PM ET in Coral Gables, Florida.
Live webcasts of the presentations will be available on the
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on retinal diseases, will participate in Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. The event will feature two key sessions:
1. A presentation titled 'Update on Antibody Biopolymer Conjugates: Optimizing Immediacy and Durability' at 3:30 PM CT by Dr. Mark Barakat, Clinical Assistant Professor of Ophthalmology at the University of Arizona College of Medicine – Phoenix.
2. A panel discussion on 'The Future of Retinal Therapeutics' at 6:30 PM CT, featuring Victor Perlroth, M.D., Chairman and CEO of Kodiak Sciences.
Presentation slides will be available on Kodiak's website in the 'Events and Presentations' section at the start of the presentation.
Kodiak Sciences (Nasdaq: KOD) is hosting its Investor R&D Day today in New York from 10:30 am to 12:30 pm ET. The event can be accessed virtually and will feature presentations from Kodiak's leadership team and leading retina specialist key opinion leaders. The agenda includes discussions on the science of durability, enhanced formulation, clinical program overview, and the Kodiak opportunity.
Speakers include David Brown, MD, Clinical Professor of Ophthalmology at Baylor College of Medicine, and Charles Wykoff, MD, PhD, Clinical Professor of Ophthalmology at Weill Cornell Medical College. The event will also preview Kodiak's ABCD Platform and conclude with a summary and audience Q&A session.
A live webcast, replay, and presentation slides will be available on Kodiak's Investors & Media website. This event provides an opportunity for investors to gain insights into Kodiak's research and development efforts in the field of ophthalmology.
Kodiak Sciences (Nasdaq: KOD) will host an Investor R&D Day on September 23, 2024, in New York City from 10:30 am to 12:30 pm ET. The event will showcase the company's advancements in retinal disease therapeutics, featuring presentations on:
1. The science behind their Antibody Biopolymer Conjugate (ABC) Platform, including new data on human ocular half-life.
2. Enhanced formulations for tarcocimab and KSI-501, designed for improved immediacy and administration.
3. Updates on ongoing clinical trials and pipeline programs.
4. The evolution to their Antibody Biopolymer Conjugate Drug (ABCD) Platform.
Featured speakers include Kodiak's executive team and renowned retina specialists. The event will be webcast live and available for replay on Kodiak's website.
Kodiak Sciences (Nasdaq: KOD) reported Q2 2024 financial results and business highlights. Key points include:
- Clinical progress: Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy continues enrollment. Phase 3 DAYBREAK study of tarcocimab and KSI-501 in wet AMD is now enrolling. Phase 1b APEX study of KSI-101 in macular edema is also enrolling.
- Leadership appointments: New Chief Scientific Officer, Chief Quality Officer, Chief Technology Officer, and Chief Medical Officer.
- Financial results: Q2 net loss of $45.1 million ($0.86 per share). Cash position of $219.2 million, expected to support operations into 2026.
- R&D expenses: $32.5 million in Q2, down from $67.0 million in Q2 2023.
- G&A expenses: $15.5 million in Q2, down from $17.9 million in Q2 2023.
The company plans to host an Investor Day on September 23, 2024.
Kodiak Sciences (Nasdaq: KOD), a biopharmaceutical company focused on retinal diseases, announced upcoming presentations at several key conferences.
They'll present at the Jefferies Healthcare Conference on June 6, 2024, in New York, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 13, 2024, in Miami Beach. Live webcasts will be available on their website.
Kodiak will also attend the Clinical Trials at the Summit 2024 on June 8 in Park City. Key presentations will be made by Quan Dong Nguyen, M.D., and CEO Victor Perlroth, M.D., highlighting their bispecific anti-IL-6 and anti-VEGF programs, KSI-501 and KSI-101.
Slides will be accessible on Kodiak's website during the presentations.